The monoclonal antibody ustekinumab (Stelara), which targets interleukin (IL)-12 and IL-23, appeared to be effective for clearing oral ulcers in Behcet's disease in a multicenter open-label study ...

Soligenix Inc. (NASDAQ:SNGX) shares surged on Thursday as the company announced positive results from its Phase 2a ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and ...

Behçet's Disease, also known as Behçet's Syndrome, affects approximately 5 in 100,000 people in the U.S. 1,2 Oral ulcers, the most common manifestation of Behçet's Disease occurring in more ...

Soligenix Inc.’s phase IIa study of SGX-945 (dusquetide) for treating oral ulcers in those with Behçet's disease showed biological efficacy in the proof-of-concept study. The positive results ...

There are approximately 18,000 known cases of Behçet's Disease in the U.S. and 80,000 in Europe. There are as many as 1,000,000 people worldwide living with Behçet's Disease.

Soligenix, Inc., a late-stage biopharmaceutical company, announced that its SGX945 (dusquetide) development programme for the treatment of oral lesions of Behçet’s disease has received “Fast Track” ...

Genital ulcers seen with BD are usually found on the scrotum or labiae. Oral ulcers (85%), genitalulcers (21.7%) and articular symptoms (16.7%) have been reported as the most common onset ...

These antibodies, usually found in 50-60% of patients with Crohn's disease, were postulated to be a new seromarker for BD by Krause et al. (see also 'Patient with oral ulcers' section). [9] ...

Under this IND, the pilot clinical trial of SGX945 will be an open-label study that will enroll approximately 25 patients age 18 years or older with mild to moderate Behçet's disease active oral ...